Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

Leukemia

Volumn 22, Issue 6, 2008, Pages 1282-1284

  Paripati, H ^a   Stewart, A K ^a   Cabou, S ^a   Dueck, A ^a   Zepeda, V J ^a   Pirooz, N ^a   Ehlenbeck, C ^a   Reeder, C ^a   Slack, J ^a   Leis, J F ^a   Boesiger, J ^a   Torloni, A S ^a   Fonseca, R ^a   Bergsagel, P L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR; THALIDOMIDE; VINCRISTINE;

ARTICLE; CD34 SELECTION; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MYELOMA; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

EID: 44649143334     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405100     Document Type: Article

References (9)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM et al. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
3. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
4. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B et al Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeioma. Mayo Clin Proc 2007; 82: 1179-1184.
5. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
6. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: Influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294-1299.
7. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): Consensus statement. Mayo Clin Proc 2007; 82: 323-341.
8. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042.
9. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2007 (in press).